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a b s t r a c t
Objectives: The aim of this study was to evaluate the prevalence of anaemia in rheumatoid 
arthritis (RA).
Patients and methods: 89 patients who fulfilled American College of Rheumatology (ACR) cri-
teria for RA were included in this study. The mean disease duration was 10.9±8.8 years. All 
patients received methotrexate (10.5±5.5 mg/week) in combination with folic acid. Steroid 
hormones were prescribed to 92% (19.3±3.8 mg/day) of patients. Erythrocyte sedimentation 
rate (ESR) and levels of hemoglobin, C-reactive protein (CRP), tumour necrosis factor-alpha 
(TNFα) and interleukin-1 beta (IL-1β) were evaluated in all patients. The World Health Or-
ganization (WHO) criteria for anaemia uses a hemoglobin threshold of <120 g/L for women 
and <130 g/L for men.
Results: Anaemia was observed in 57 (64%) of the patients (1st group), the other patients (2nd 
group) had normal levels of hemoglobin (135.5±10.7 g/L). Duration and activity of RA were 
significantly higher (p<0.05) in the 1st group compared with the 2nd. ESR, CRP, TNFα, and IL-
1β mean levels were significantly increased (p<0.05) in the 1st group when compared with 
the 2nd group. Negative correlations between hemoglobin level and ESR, CRP, TNFα, and IL-
1β concentrations were observed.
Conclusion: This study showed for the first time in Ukraine that in 46% of patients with RA, 
anaemia was diagnosed. A reduction of hemoglobin level was associated with a high acti-
vity of disease. 
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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r e s u m o
Objetivos: O objetivo desse estudo foi avaliar a prevalência de anemia em pacientes com 
artrite reumatoide (AR).
Pacientes e métodos: 89 pacientes que satisfaziam os critérios do American College of Rheuma-
tology (ACR) para AR foram incluídos nesse estudo. A duração média da doença foi 10,9±8,8 
anos. Todos os pacientes foram medicados com metotrexato (10,5±5,5 mg/semana) em 
combinação com ácido fólico. Hormônios esteroides foram receitados para 92% dos paci-
entes (19,3±3,8 mg/dia). Velocidade de hemossedimentação (VHS), níveis de hemoglobina, 
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proteína C reativa (PCR), fator de necrose tumoral alfa (TNFα) e interleucina-1 beta (IL-
1β) foram avaliados em todos os pacientes. Os critérios da Organização Mundial da Saúde 
(OMS) para anemia utilizam um limiar para hemoglobina de <120 g/L para mulheres e de 
<130 g/L para homens.
Resultados: Anemia foi observada em 57 (64%) dos pacientes (1º grupo); os demais pacientes 
(2º grupo) tinham níveis normais de hemoglobina (135,5±10,7 g/L). A duração e a atividade 
de AR foram significativamente maiores (p<0,05) no 1º versus 2º grupo. Os níveis médios 
de VHS, PCR, TNFα e IL-1β estavam significativamente aumentados (p<0,05) no 1º versus 2º 
grupo. Foram observadas correlações negativas entre o nível de hemoglobina e as concen-
trações de VHS, PCR, TNFα e IL-1β.
Conclusão: Esse estudo demonstrou pela primeira vez que, na Ucrânia, 46% dos pacientes 
com AR apresentavam anemia. Um nível reduzido de hemoglobina foi associado à ativi-
dade intensa da doença.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Rheumatoid arthritis (RA) is a polyarticular autoimmune 
disease, affecting about 1% of the adult population.1 The dis-
ease is characterized by hyperplasia of synoviocytes, mainly 
the synovial fibroblasts, resulting in bone and joint destruc-
tion.2 Recent studies have revealed a key role of cytokines 
and other mediators of inflammation in the development 
not only of the articular syndrome, but also a whole range 
of systemic manifestations of the disease.3 In particular, 
anemic syndrome is a very common manifestation of rheu-
matoid inflammation. However, the prevalence of anemia in 
Ukrainian patients has never been investigated as it relates 
to RA.
The aim of this study was to determine the prevalence of 
anemia in RA patients.
Methods
Eighty-nine patients who fulfilled the American College of 
Rheumatology (ARA) criteria for RA were included in this 
study. The mean disease duration was 10.9±8.8 years. All 
patients received methotrexate (average dose 10.5±5.5 mg/
week) in combination with folic acid. Steroid hormones were 
prescribed to 92% (average dose 19.3±3.8 mg/day). All of the 
subjects were submitted to the following battery of tests: 
erythrocyte sedimentation rate (ESR), levels of hemoglobin, 
C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-Į) 
and interleukin-1 beta (IL-1ȕ). The World Health Organization 
(WHO) criteria for anemia uses a hemoglobin threshold of 
<120 g/L for women and <130 g/L for men.4 Pregnant or breast-
feeding patients, patients with a history of other inflamma-
tory or non-inflammatory arthritis, megaloblastic anemia, 
malignancies, renal disease with severe renal insufficiency, 
chronic infectious and inflammatory diseases, and other dis-
eases in the stage of decompensation were excluded from the 
study. In addition, the study was approved by the local ethics 
committee, and all participants gave their written consent for 
inclusion.
Statistical analysis
The Kolmogrov-Smirnov and Shapiro-Wilk tests were used to 
test normality while non-parametric tests were preferred for 
testing the results and scales. The differences in proportions 
between the groups were compared using a chi-square or 
Fisher’s exact test where appropriate. Continuous variables, 
including disease duration, and morning stiffness (MS) dura-
tion were compared using the Mann-Whitney-U test among 
categories of grouped variables, and the degree of correlation 
between the variables was calculated using Spearman’s rho 
correlation coefficients. General descriptive statistics were 
summarized using numbers and percentages for categorical 
variables and median (min-max) while mean ± standard de-
viation (SD) was utilized for continuous variables. Statistical 
analyses were performed with the “MedStat” version 4.0 for 
Windows software program, and a p-value of less than 0.05 
was considered to be statistically significant.
Results
Anemia was observed in 57 (64%) of the patients (1st group); the 
other (2nd group) had normal levels of hemoglobin (135.5±10.7 
g/L). The patients from the 1st and 2nd groups were statistically 
similar with regard to age (p=0.21) and gender (p=0.33).
Duration and activity of RA were significantly (p<0.05) 
higher in 1st group compared with the 2nd (Table 1). The mean 
ESR, CRP, TNF-a, IL-1b levels were significantly increased in 
the 1st group when compared with the 2nd (Table 1). 
The results of a correlation analysis between the hemo-
globin level and the laboratory parameters of RA activity are 
shown in Table 2. There were negative correlations between 
the hemoglobin level and ESR, CRP, TNF-a, IL-1b concentra-
tions (Table 2). 
Discussion 
According to the literature,5 anemia develops in 30%-70% 
of patients with RA. There are different types of anemia, 
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including iron deficiency anemia (IDA), anemia of chronic 
disease (ACD), megaloblastic anemia, hemolytic anemia 
and COMBI anemia that could occur in patients with RA. 
Some causes of anemia include changes in iron metabolism 
due to lesions of the mucous membrane of the gastrointes-
tinal tract by steroid drugs, methotrexate; shortening of red 
blood cells’ life or its inadequate production by bone mar-
row.6 Our results are consistent with the data of literature. 
A characteristic of this disorder is a blunted erythropoietin 
response by red blood cell precursors, decreased survival 
of the red blood cells, and defective iron absorption. Defec-
tive macrophage iron retention may also contribute to the 
disorder by interrupting iron delivery to erythroid precur-
sor cells. It may be precipitated by impaired iron utiliza-
tion, where functional iron is low but tissue iron is nor-
mal or high. It is the second most common form of anemia 
worldwide after IDA. It is also clear now that inflammatory 
cytokines released during ACD can alter systemic iron me-
tabolism by inducing excess synthesis of hepcidin, the iron 
regulatory hormone. Since hepcidin inhibits iron export 
from cells by blocking ferroportin activity, excess hepcidin 
is the root cause of the hypoferremia and iron-restricted 
erythropoiesis seen in ACD. 
Conclusions 
In conclusion, we believe that this is the first study to evaluate 
the prevalence of anemia in Ukrainian patients with RA. We 
suggest that RA patients undergo a routine analysis of their 
hemoglobin levels, and when decreased hemoglobin level 
is suspected, adequate investigation should be performed. 
Moreover, patients should be advised about estimation of 
clinical and laboratory RA activity parameters.
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Table 1 – Comparison of the RA activity of the two groups
Parameters P-values 1st group 2nd group
Duration of RA 0.004 11,67±3,62 7,63±3,48
ESR, mm/h 0.03 51,26±24,67 29,65±19,84
CRP, mg/dL 0.001 48,27±12,18 4,38±1,28
TNFĮ, pcg/mL 0.001 32,54±9,71 7,69±3,45
IL-1ȕ, pg/mL 0.04 166,32±18,54 102,28±16,34
DAS28 index 0.004 5(5;6,5) 3(2,5;3)
Table 2 – The results of a correlation analysis between 
the hemoglobin level and the laboratory parameters of 
RA activity
Laboratory test Correlation 
coefficient (r)
p values
ESR, mm/h -0,62 p<0,001
CRP, mg/dL -0,61 p<0,001
TNF-Į, pcg/mL -0,59 p<0,001
IL-1ȕ, pg/mL -0,57 p<0,001
